Optimizing Your Imaging Strategy
BioShowDaily – May 18, 2009
Preclinical imaging has become widely recognized in recent years as a valuable tool for improving the efficiency and accuracy of the drug discovery and development process. As a result, modalities such as magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and bioluminescence imaging are being embraced by the pharmaceutical industry. While accepting the technology is the first step, utilizing it in a successful way encompasses three critical steps: seamlessly interfacing imaging expertise across multiple scientific disciplines; understanding and accounting for the limitations of preclinical imaging; and balancing throughput with image sensitivity and resolution.
Drug discovery is driven by pharmacologists, biologists, chemists and other life science experts, while imaging involves an expertise all its own. As a result, it is vital to have access to both types of experts and, just as important, to maintain a seamless interface between these two groups of experienced personnel...Read the full article.